通过PRMT5介导的FUBP1甲基化加速前列腺癌的进展
Weiwei Yan1, Xun Liu2, Xuefeng Qiu3
1Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
The Journal of clinical investigation
|August 15, 2024
概括
针对FUBP1甲基化,对于前列腺癌的进展至关重要,提供了一个新的治疗策略. 一种新破坏了FUBP1甲基化,在临床前模型和患者数据中抑制了癌症的发展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 与激素相关的疗法不足以改善前列腺癌的生存率.
- 需要针对前列腺癌进展的新疗法策略.
研究的目的:
- 研究FUBP1甲基化在前列腺癌发展中的作用.
- 评估一种针对前列腺癌FUBP1甲基化的基于酸的新型疗法.
主要方法:
- 在临床前前列腺癌模型中研究了FUBP1甲基化.
- 利用具有FUBP1突变的基因小鼠模型.
- 开发并测试了一种通过纳米复合体输送的,以破坏FUBP1-PRMT5相互作用.
- 与患者结局相关的FUBP1甲基化.
主要成果:
- FUBP1及其甲基化对前列腺癌的进展至关重要.
- 由BRD4调节的PRMT5介导的FUBP1甲基化,驱动瘤效应.
- 在患者中,FUBP1甲基化与早期生化复发相关.
- 在模型中,竞争性酸成功地阻断了FUBP1甲基化,并抑制了瘤生长.
结论:
- 准FUBP1甲基化为前列腺癌提供了一个有前途的治疗途径.
- 破坏FUBP1-PRMT5相互作用的基于的策略显示了前列腺癌治疗的潜力.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K


